- Senate passes Drug Quality and Security Act
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- PhRMA report lists 271 vaccines in development
- Walgreens partners with United Nations Foundation's Shot@Life campaign
- Kathy Ireland's brand kiWW forms alliance to develop skin care devices
SILVER SPRING, Md. — The Food and Drug Administration has approved a treatment for a rare bleeding disorder.
The FDA announced the approval of Corifact, used to prevent bleeding in people with the genetic disorder congenital Factor XIII deficiency, which affects 1-in-3 million to 5 million people in the United States.
The drug is manufactured by Marburg, Germany-based CSL Behring.